How should trial issues be escalated and followed up by the sponsor?

Boost your GCP E6 (R3) exam readiness. Improve your understanding with engaging, insightful questions. Test yourself with hints and detailed explanations. Prepare effectively!

Multiple Choice

How should trial issues be escalated and followed up by the sponsor?

In Good Clinical Practice, the sponsor has the ongoing duty to oversee the trial and protect participant safety and data integrity. When issues arise—anything that could affect safety, data quality, or compliance—the sponsor must have a clear path to escalate them to the right people at the right time and then actively follow up to ensure actions are taken and effective. This means promptly notifying appropriate stakeholders, assigning owners, initiating corrective and preventive actions, setting timelines, and verifying that those actions actually resolved the issue. A formal escalation and follow-up process helps prevent risks from escalating, ensures regulatory and ethical obligations are met, and provides auditable evidence that problems were addressed. Delaying escalation until the end of the trial would miss opportunities to mitigate risk and could compromise participant safety and data integrity. Escalation is not the sole responsibility of investigators; the sponsor bears the responsibility for oversight and timely intervention. And escalation should not be avoided or postponed unless there’s no alternative—proactive, documented action is the aim to effectively manage trial issues.

In Good Clinical Practice, the sponsor has the ongoing duty to oversee the trial and protect participant safety and data integrity. When issues arise—anything that could affect safety, data quality, or compliance—the sponsor must have a clear path to escalate them to the right people at the right time and then actively follow up to ensure actions are taken and effective. This means promptly notifying appropriate stakeholders, assigning owners, initiating corrective and preventive actions, setting timelines, and verifying that those actions actually resolved the issue. A formal escalation and follow-up process helps prevent risks from escalating, ensures regulatory and ethical obligations are met, and provides auditable evidence that problems were addressed.

Delaying escalation until the end of the trial would miss opportunities to mitigate risk and could compromise participant safety and data integrity. Escalation is not the sole responsibility of investigators; the sponsor bears the responsibility for oversight and timely intervention. And escalation should not be avoided or postponed unless there’s no alternative—proactive, documented action is the aim to effectively manage trial issues.

More practice questions